Funding Alzheimer's Tx Dev with ADDF's Karen Harris
Apr 1, 2024
auto_awesome
Karen Harris, CFO of ADDF, shares insights on funding Alzheimer's therapies and the value of venture philanthropy in biotech. She discusses the challenges in securing funding, the shift towards aging biology in treatments, and the investments in CNS-related work. The episode delves into the relationship between anti-aging research and neurodegenerative diseases, emphasizing the importance of Alzheimer's research and venture philanthropy in biotech funding.
ADDF implements a unique venture philanthropy model, directly investing in biotechs to accelerate Alzheimer's drug development.
ADDF channels support into novel Alzheimer's therapeutics, emphasizing precision medicine and combination therapies for impactful treatments.
Deep dives
Venture Philanthropy and Biotech Funding
Venture philanthropy emerges as a bright spot in the biotech funding landscape. Focused on accelerating drug discovery for Alzheimer's disease, the Alzheimer's Drug Discovery Foundation (ADDF) stands out. Founded by the Lauder family and bolstered by prominent supporters like Bill Gates and Jeff Bezos, ADDF functions as a venture philanthropy fund, investing in biotechs developing Alzheimer's therapeutics with returns reinvested into the fund.
Unique Venture Philanthropy Model
ADDF implements a unique venture philanthropy model by investing directly in biotechs instead of providing grants. Through strategic investments akin to venture capitalists, ADDF aims to advance drug development for Alzheimer's. The CFO of ADDF navigates the financial landscape ensuring efficient allocation of donor funds to drive progress in Alzheimer's research.
Focus on Therapeutics and Diagnostics
ADDF channels its support towards therapeutic development, diagnostics, and prevention strategies for Alzheimer's disease. By investing in companies targeting the underlying biology of aging, ADDF pioneers novel approaches beyond conventional amyloid-focused treatments. The emphasis on precision medicine and combination therapies underscores a strategic shift towards more impactful treatment modalities.
Navigating the Biotech Market and Investment Trends
In a challenging biotech market, ADDF provides bridge financing to support companies facing funding hurdles. The evolving economic climate impacts biotech investments, with ADDF strategically aligning with burgeoning trends like anti-aging research. Leveraging its scientific expertise and strategic investments, ADDF remains steadfast in its mission to advance breakthroughs in Alzheimer's therapeutics.
We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the sometimes tumultuous Alzheimer's therapeutics space is valuable to any drug developer working in the cognitive medicines arena. In this episode of the Business of Biotech podcast, we follow Karen's journey from institutional investment banking to the incredibly gratifying work she does now, helping to fund the novel biopharma companies that are working in earnest to solve an emotionally burdensome and expensive problem. Karen shares ADDF's strategy and offers plenty of insight into the value proposition that venture philathropy offers the biotech community. Tune in!
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.